Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study

BACKGROUND: To support public health measures during the COVID-19 pandemic, oral opioid agonist treatment (OAT) take-home doses were expanded in Western countries with positive results. Injectable OAT (iOAT) take-home doses were previously not an eligible option, and were made available for the firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Oviedo-Joekes, Eugenia, Dobischok, Sophia, Carvajal, José, MacDonald, Scott, McDermid, Cheryl, Klakowicz, Piotr, Harrison, Scott, LaJeunesse, Julie, Chow, Nancy, Brown, Murray, Gill, Sam, Schechter, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215060/
https://www.ncbi.nlm.nih.gov/pubmed/37237256
http://dx.doi.org/10.1186/s12913-023-09558-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215060/
https://www.ncbi.nlm.nih.gov/pubmed/37237256
http://dx.doi.org/10.1186/s12913-023-09558-6

Ejemplares similares